Variable | No. at riska | No. of events | 3-month survival, % ± SD | Univariate Cox regression analysis | Multivariate Cox regression analysis | ||||
---|---|---|---|---|---|---|---|---|---|
HR | 95% CI | P-value | HR | 95% CI | P-value | ||||
Age | |||||||||
< 55 years old | 47 | 33 | 57 ± 7 | 1.000 | (reference) | ||||
≥ 55 years old | 53 | 44 | 45 ± 7 | 1.269 | 0.802–2.007 | 0.307 | |||
Gender | |||||||||
Male§ | 74 | 60 | 46 ± 6 | 1.845 | 1.066–3.194 | 0.029 | 3.211 | 1.709–6.034 | < 0.001 |
Female | 26 | 17 | 65 ± 9 | 1.000 | (reference) | 1.000 | (reference) | ||
Body mass index | |||||||||
Underweight | 31 | 24 | 48 ± 9 | 1.108 | 0.658–1.865 | 0.700 | |||
Normal weight | 44 | 35 | 50 ± 8 | 1.000 | (reference) | ||||
Overweight | 25 | 18 | 55 ± 10 | 0.796 | 0.468–1.468 | 0.519 | |||
Sarcopenia | |||||||||
No | 69 | 49 | 62 ± 6 | 1.000 | (reference) | 1.000 | (reference) | ||
Yesc | 31 | 28 | 26 ± 8 | 2.950 | 1.836–4.740 | <.0.001 | 1.921 | 1.129–3.268 | 0.016 |
IMF deposition | |||||||||
No | 35 | 17 | 89 ± 5 | 1.000 | (reference) | 1.000 | (reference) | ||
Yesc | 65 | 60 | 31 ± 6 | 5.487 | 3.106–9.693 | <.0.001 | 3.580 | 1.895–6.764 | < 0.001 |
Visceral adiposity | |||||||||
No | 71 | 55 | 48 ± 6 | 1.000 | (reference) | ||||
Yes | 29 | 22 | 59 ± 6 | 0.890 | 0.542–1.461 | 0.644 | |||
Viral status | |||||||||
HBV | 58 | 51 | 40 ± 6 | 2.326 | 1.380–3.920 | 0.002 | 1.223 | 0.708–2.114 | 0.471 |
HCV | 8 | 6 | 50 ± 18 | 1.338 | 0.536–3.340 | 0.533 | |||
None | 34 | 20 | 71 ± 8 | 1.000 | (reference) | 1.000 | (reference) | ||
Child-Pugh class | |||||||||
A | 60 | 42 | 68 ± 6 | 1.000 | (reference) | 1.000 | (reference) | ||
B | 32 | 27 | 28 ± 8 | 2.129 | 1.306–3.469 | 0.002 | 0.406 | 0.087–1.901 | 0.252 |
C | 8 | 8 | 13 ± 12 | 5.069 | 2.342–10.973 | <.0.001 | 0.578 | 0.110–3.031 | 0.516 |
TNM-AJCC stage AJCC - 8th Edition | |||||||||
TNM-AJCC 1 | 20 | 13 | 85 ± 8 | 1.000 | (reference) | 1.000 | (reference) | ||
TNM-AJCC 2 | 5 | 5 | 60 ± 22 | 3.586 | 1.244–10.339 | 0.018 | 1.304 | 0.439–3.875 | 0.633 |
TNM-AJCC 3 | 32 | 21 | 56 ± 9 | 1.618 | 0.797–3.286 | 0.183 | |||
TNM-AJCC 4 | 43 | 38 | 30 ± 7 | 3.663 | 1.908–7.031 | <.0.001 | 1.177 | 0.341–4.063 | 0.796 |
TNM-LCSGJ stage | |||||||||
TNM-LCSSGJ 2 | 21 | 14 | 86 ± 8 | 1.000 | (reference) | 1.000 | (reference) | ||
TNM-LCSSGJ 3 | 32 | 22 | 53 ± 9 | 1.687 | 0.850–3.347 | 0.135 | |||
TNM-LCSSGJ 4 | 47 | 41 | 34 ± 7 | 3.308 | 1.763–6.206 | <.0.001 | 0.835 | 0.453–1.542 | 0.565 |
JIS score | |||||||||
JIS score 1 | 18 | 12 | 89 ± 7 | 1.000 | (reference) | 1.000 | (reference) | ||
JIS score 2 | 23 | 15 | 61 ± 10 | 1.426 | 0.737–4.494 | 0.362 | |||
JIS score 3 | 31 | 23 | 54 ± 9 | 2.128 | 0.818–4.409 | 0.038 | 1.642 | 0.679–3.974 | 0.271 |
JIS score 4c | 23 | 22 | 17 ± 8 | 4.802 | 2.053–6.205 | < 0.001 | 2.067 | 1.119–3.817 | 0.020 |
JIS score 5 | 5 | 5 | 0 ± 0 | 28.373 | 8.802–91.456 | <.0.001 | 3.843 | 0.938–15.735 | 0.061 |
BCLC stage | |||||||||
A | 7 | 2 | 100 ± 0 | 1.000 | (reference) | 1.000 | (reference) | ||
B | 25 | 13 | 88 ± 7 | 3.817 | 0.829–17.584 | 0.086 | |||
C§ | 59 | 53 | 37 ± 6 | 12.419 | 2.907–53.067 | 0.001 | 2.396 | 1.248–4.600 | 0.009 |
D§ | 9 | 9 | 0 ± 0 | 65.958 | 12.94–336.25 | < 0.001 | 6.131 | 1.835–20.478 | 0.003 |
AFP level | |||||||||
< 200 ng/ml | 48 | 33 | 62 ± 7 | 1.000 | (reference) | 1.000 | (reference) | ||
≥ 200 ng/ml | 52 | 44 | 40 ± 7 | 1.916 | 1.210–3.034 | 0.006 | 1.063 | 0.636–1.777 | 0.815 |